// App-Quantinova.ai

3269 : Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

Researchers

Presenter

  • Martin Hutchings

Principal Investigators

  • Francesc Bosch

  • Giuseppe Gritti

  • Carmelo Carlo-Stella

  • Harriet Walter

  • William Townsend

  • Franck Morschhauser

  • Guillaume Cartron

  • Herv Ghesquieres

  • Sophie de Guibert

  • Sylvia Herter

  • Koorosh Korfi

  • Veronica Craine

  • Sarah Louise Mycroft

  • Matt Whayman

  • Claudia Mueller

  • Natalie Dimier

  • Tom Moore

  • Sara Belli

  • Martin Kornacker

  • Katharina Lechner

  • Michael Dickinson

Medical Centers

  • Department of Hematology; Finsen Centre, National Hospital, Copenhagen University Hospital, Copenhagen, Denmark

  • University Hospital Gent, Gent, Belgium

  • Department of Hematology, University Hospital Vall d’Hebron, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain

  • Papa Giovanni XXIII Hospital, Bergamo, Italy

  • Humanitas Clinical and Research Center - IRCCS,Humanitas University,Milan,Italie

  • 6The HOPE Clinical Trials Unit, Leicester, United Kingdom

  • King's Coll London, The Rayne Inst, London, United Kingdom

  • Department of Hematology, Centre Hospitalier regional universitaire, Lille, France

  • Centre Hospitalier Universitaire, Montpellier, Montpellier, France

  • Department of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France

  • Centre Hospitalier Universitaire, Ottignies, France

  • Roche Innovation Center Zurich,Roche Pharma Research and Early Development,Zurich,Schweiz

  • A4P Consulting Ltd, Sandwich, United Kingdom

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Roche Innovation Center Welwyn, Roche Ltd, Welwyn, United Kingdom

  • Roche Innovation Center Penzberg, Roche Pharmaceutical Research and Early Development, Penzberg, Germany

  • Roche Innovation Center Zurich,Roche Pharma Research and Early Development,Zurich,Schweiz

  • Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Denmark

  • Belgium

  • Spain

  • Italy

  • United Kingdom

  • France

  • Switzerland

  • Canada

  • Germany

  • Australia

Companies

  • A4P Bio Consulting L

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 19

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Fixed Dose

  • Open Label

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT04077723

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved